U.S. pharma huge copyright scrapped two experimental weight loss tablets last year—a when-daily tablet, lotiglipron, resulting from elevated liver enzymes and a twice-every day capsule, danuglipron, because of potent Uncomfortable side effects—but CEO Albert Bourla has stated the com